Congress Puts 'Shadow' Pricing Of MS Drugs in the Spotlight.
Lawmakers asked seven companies to explain not only "skyrocketing prices," but a practice known as shadow pricing in which a drugmaker increases the price of an existing medicine to match the price hike or higher price set for a new drug launched by another company.